BR0015580A - Composições analgésicas contendo buprenorfina - Google Patents

Composições analgésicas contendo buprenorfina

Info

Publication number
BR0015580A
BR0015580A BR0015580-2A BR0015580A BR0015580A BR 0015580 A BR0015580 A BR 0015580A BR 0015580 A BR0015580 A BR 0015580A BR 0015580 A BR0015580 A BR 0015580A
Authority
BR
Brazil
Prior art keywords
buprenorphine
compositions containing
nalmefene
naltrexone
naloxone
Prior art date
Application number
BR0015580-2A
Other languages
English (en)
Inventor
Christopher Bourne Chapleo
Keith Mccormack
Nicolas Calvert Varey
Original Assignee
Reckitt Benckiser Healthcare
Mited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927359.1A external-priority patent/GB9927359D0/en
Application filed by Reckitt Benckiser Healthcare, Mited filed Critical Reckitt Benckiser Healthcare
Publication of BR0015580A publication Critical patent/BR0015580A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçõES ANALGéSICAS CONTENDO BUPRENORFINA ". Composição analgésica na forma de dosagem unitária parenteral, ou em uma forma de dosagem adequada para distribuição via mucosa, compreendendo uma quantidade de buprenorfina que é inferior à dose clínica necessária para alcançar alívio da dor; e uma quantidade de naloxona de modo que a relação em peso de buprenorfina para naloxona seja na faixa de 12,5:1 a 27,5:1, ou uma quantidade de naltrexona ou nalmefeno de modo que a relação em peso de buprenorfina para naltrexona ou nalmefeno seja na faixa de 12,5:1 a 22,5:1, com o que a ação analgésica da buprenorfina é potencializada pela baixa dose de naloxona, naltrexona ou nalmefeno.
BR0015580-2A 1999-11-19 2000-11-17 Composições analgésicas contendo buprenorfina BR0015580A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9927359.1A GB9927359D0 (en) 1999-11-19 1999-11-19 Improvements in or relating to organic compositions
US17620800P 2000-01-14 2000-01-14
PCT/GB2000/004372 WO2001035942A2 (en) 1999-11-19 2000-11-17 Analgesic compositions containing buprenorphine

Publications (1)

Publication Number Publication Date
BR0015580A true BR0015580A (pt) 2002-07-09

Family

ID=26316086

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015580-2A BR0015580A (pt) 1999-11-19 2000-11-17 Composições analgésicas contendo buprenorfina

Country Status (30)

Country Link
US (4) US6995169B2 (pt)
EP (1) EP1242087B1 (pt)
JP (1) JP4745576B2 (pt)
KR (1) KR100726699B1 (pt)
CN (1) CN100431543C (pt)
AR (1) AR031682A1 (pt)
AT (1) ATE262335T1 (pt)
AU (1) AU777259B2 (pt)
BR (1) BR0015580A (pt)
CA (1) CA2392013C (pt)
CO (1) CO5261517A1 (pt)
CZ (1) CZ303160B6 (pt)
DE (1) DE60009346T2 (pt)
DK (1) DK1242087T3 (pt)
ES (1) ES2214334T3 (pt)
GB (1) GB2356348B (pt)
HU (1) HU229565B1 (pt)
IL (2) IL149580A0 (pt)
MX (1) MXPA02004978A (pt)
NO (1) NO321965B1 (pt)
NZ (1) NZ519023A (pt)
PL (1) PL199727B1 (pt)
PT (1) PT1242087E (pt)
RO (1) RO121174B1 (pt)
RU (1) RU2255737C2 (pt)
SI (1) SI21025B (pt)
SK (1) SK286888B6 (pt)
TR (1) TR200400653T4 (pt)
TW (1) TW550070B (pt)
WO (1) WO2001035942A2 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20150031718A1 (en) * 2001-08-06 2015-01-29 Purdue Pharma L.P. Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
RU2350327C2 (ru) 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Составы, вызывающие потерю веса
DK1765292T3 (en) 2004-06-12 2018-01-02 Collegium Pharmaceutical Inc ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
CA2674915C (en) 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
EP2089010A1 (en) 2006-10-24 2009-08-19 The John Hopkins University Rapid release mini-tablets provide analgesia in laboratory animals
CA2668885C (en) * 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US20080199407A1 (en) 2007-02-15 2008-08-21 Slater Kenneth C Drug Detoxification Protocol Using Microdosing
GB2447015A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene
GB2447014A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
WO2009032246A2 (en) 2007-09-03 2009-03-12 Nanotherapeutics, Inc. Particulate compositions for delivery of poorly soluble drugs
US20090082383A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched buprenorphine
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP3659604A1 (en) * 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
CA2991216C (en) 2010-12-22 2020-04-28 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
MY185284A (en) 2011-09-19 2021-04-30 Orexo Ab New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
PT3730132T (pt) 2012-06-06 2022-08-16 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
CA2899455C (en) 2013-01-30 2021-06-08 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
ES2802976T3 (es) 2013-09-10 2021-01-22 Fresh Cut Dev Llc Pulverizador de buprenorfina sublingual
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
AU2015250611A1 (en) * 2014-04-22 2016-11-24 H. Lundbeck A/S Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
WO2021158957A1 (en) * 2020-02-05 2021-08-12 Summit Biosciences Inc. Drug products for intranasal administration and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
GB8430109D0 (en) 1984-11-29 1985-01-09 Gkn Technology Ltd Securing components
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
GB2213058B (en) * 1987-12-03 1991-07-17 Reckitt & Colmann Prod Ltd Compositions comprising buprenorphine and naltrexone for treatment of opiate addicts
US20010006967A1 (en) * 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
RU2077326C1 (ru) * 1992-12-29 1997-04-20 Ярыгин Владимир Никитич Препарат для анальгезии
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
AU2001259458B2 (en) * 2000-05-05 2006-09-14 Albert Einstein College Of Medicine Of Yeshiva University Opioid antagonist compositions and dosage forms

Also Published As

Publication number Publication date
MXPA02004978A (es) 2003-01-28
SI21025A (sl) 2003-04-30
US20030004178A1 (en) 2003-01-02
DK1242087T3 (da) 2004-07-19
US20060058333A1 (en) 2006-03-16
JP4745576B2 (ja) 2011-08-10
RO121174B1 (ro) 2007-01-30
IL149580A0 (en) 2002-11-10
CA2392013A1 (en) 2001-05-25
HK1055389A1 (zh) 2004-01-09
IL149580A (en) 2007-05-15
ATE262335T1 (de) 2004-04-15
NO20022330D0 (no) 2002-05-15
AR031682A1 (es) 2003-10-01
KR20020058022A (ko) 2002-07-12
TW550070B (en) 2003-09-01
EP1242087B1 (en) 2004-03-24
HUP0203588A3 (en) 2005-01-28
CA2392013C (en) 2009-08-11
NO321965B1 (no) 2006-07-31
RU2002116361A (ru) 2004-01-27
EP1242087A2 (en) 2002-09-25
US6995169B2 (en) 2006-02-07
AU777259B2 (en) 2004-10-07
GB2356348B (en) 2002-02-06
AU1529701A (en) 2001-05-30
NO20022330L (no) 2002-07-04
SI21025B (sl) 2008-04-30
NZ519023A (en) 2004-11-26
PT1242087E (pt) 2004-06-30
SK8762002A3 (en) 2002-12-03
DE60009346T2 (de) 2005-02-10
HUP0203588A2 (hu) 2003-03-28
US20060069113A1 (en) 2006-03-30
CO5261517A1 (es) 2003-03-31
CN100431543C (zh) 2008-11-12
CN1413110A (zh) 2003-04-23
PL199727B1 (pl) 2008-10-31
KR100726699B1 (ko) 2007-06-13
TR200400653T4 (tr) 2004-04-21
CZ303160B6 (cs) 2012-05-09
WO2001035942A3 (en) 2002-06-13
HU229565B1 (hu) 2014-02-28
WO2001035942A9 (en) 2002-11-28
US20060058332A1 (en) 2006-03-16
DE60009346D1 (de) 2004-04-29
GB0028088D0 (en) 2001-01-03
US7402591B2 (en) 2008-07-22
JP2003514013A (ja) 2003-04-15
GB2356348A (en) 2001-05-23
PL355330A1 (en) 2004-04-19
RU2255737C2 (ru) 2005-07-10
SK286888B6 (sk) 2009-07-06
ES2214334T3 (es) 2004-09-16
WO2001035942A2 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
BR0015580A (pt) Composições analgésicas contendo buprenorfina
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
BR0212019A (pt) Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
BR9813827A (pt) Analgésico opióide aplicável em mamìferos e método para impedir o uso oral abusivo de uma formulação opióide oral
IL115871A (en) Pharmaceutical composition containing a melt-extruded blend of components and a method for the preparation thereof
PA8479201A1 (es) Derivados del acido hidroxi-pipecolato hidroxamico
BR9814018A (pt) Derivados de tienopirimidina e tienopiridina úteis como agentes anticâncer
JP2003514013A5 (pt)
BR0111908A (pt) Composto, composição farmacêutica, uso do composto, e, método para o tratamento e/ou prevenção de distúrbios ou doenças
MY119403A (en) Novel compounds with analgesic effect.
BR0111257A (pt) Formulação, e, uso de uma formulação
BR0316948A (pt) Composto, formulação farmacêutica, e, uso de um composto
KR960700061A (ko) 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence)
AU2874099A (en) Low molecular weight compounds administered together with anti-cancer agents to treat cancer and pharmaceutical compositions thereof
BR0215148A (pt) Composições farmacêuticas de agonista parcial 5ht4
BRPI0413693A (pt) composição farmacêutica para a prevenção e tratamento da viciação em um mamìfero
MXPA05011432A (es) Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina.
AU1206292A (en) Therapeutic agents for the treatment of multidrug resistance to cancers
HK80492A (en) Pharmaceutical compositions with analgesic properties and the preparation and use thereof
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
BR0207866A (pt) Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
NZ326345A (en) Composition containing diosgenin
HU9203022D0 (en) Pharmaceutical preparatives with upriflavone content methods for production and medical utilization of said compounds
NZ533309A (en) Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.